Recommendations for the follow-up of study participants with breakthrough HIV infections during HIV/AIDS biomedical prevention studies.
Date
2013
Journal Title
Journal ISSN
Volume Title
Publisher
Wolters Kluwer Health.
Abstract
Objective: To facilitate collection of cumulative data on longitudinal HIV disease
outcomes during HIV prevention studies by developing recommendations for follow-up
of the relatively few study participants with breakthrough infections.
Design: We formed a working group to compare and contrast the various approaches
taken in recent HIV prevention trials, to summarize the advantages and disadvantages
associated with each, and to explore the feasibility of developing protocols for the long-term
follow-up of seroconverters.
Methods: We reviewed study designs, objectives, and assessments in 15 interventional
studies that followed HIV seroconverters. Protocol team members joined discussions of
the various approaches and developed recommendations.
Results: Most HIV prevention clinical trials share a core set of objectives, including the
description/comparison of virological, immunological, and clinical course of HIV, and
sometimes a comparison of preseroconversion and postseroconversion behavior. Long-term
follow-up of seroconverters can be conducted in separate studies if the transition
from parent protocol is effectively managed.
Conclusion: We recommend the development of harmonized seroconverter protocols.
Although specific research questions in the postseroconversion period may differ
depending on prevention modality, harmonizing key evaluations would create an
opportunity to ask overarching questions that inform the prevention field with respect to
design and implementation of future combination prevention studies. Follow-up
immediately postseroconversion should be conducted in the parent protocol before
roll over into a follow-up protocol. Development of specimen repositories with ample
volumes for future assays, standardized definitions of infection, diagnosis and seroconversion
dates, and harmonization of study objectives and sample collections at key
time points are important.
Description
CAPRISA_2013.
Keywords
Clinical trials as topic., HIV., HIV seroconversion., pathogenesis., Prevention.
Citation
Etter, P., Landovitz, R., Sibeko, S., Sobieszczyk, M.E., Riddler, S.A., Karg, C., Tsibris, A. and Schouten, J. 2013. Recommendations for the follow-up of study participants with breakthrough HIV infections during HIV/AIDS biomedical prevention studies. AIDS (London, England) 27(7), 1119-1128.